Specialist GP Nikki Vadgama provides some tips to make your next paediatric eczema consult easier. She includes a review of new guidelines, resources, websites and medications for paediatric eczema management
Reaching cholesterol targets: Which medicine to use?
Reaching cholesterol targets: Which medicine to use?
![3 Doors](/sites/default/files/styles/cropped_image_16_7_/public/2024-05/3_Doors_CR_Akriti_Singh_on_unsplash.jpg?itok=clf--x2x)
Pharmacist prescriber Linda Bryant runs through the options available to a patient on statin therapy that has been ineffective at reducing his cardiovascular risk
1. Ministry of Health. Cardiovascular Disease Risk Assessment and Management for Primary Care. Wellington, NZ: Ministry of Health; 2018.
2. Lee SJ, Joo JH, Park S, et al. Combination therapy with moderate-intensity atorvastatin and ezetimibe versus high-intensity atorvastatin monotherapy in patients treated with percutaneous coronary intervention in practice: assessing RACING generalizability. Eur Heart J Cardiovasc Pharmacother 2023; 10 November online.
3. Yu M, Liang C, Kong Q, et al. Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature. Lipids Health Dis 2020;19(1):1.
4. Lee B, Hong SJ, Rha SW, et al. Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial. Atherosclerosis 2023;386:117373.
5. Reddy V, Allison J, Mounsey A. Is there benefit to adding ezetimibe to a statin for the secondary prevention of CVD? J Fam Pract 2023;72(5):227–29.
6. Alrajeh K, AlAzzeh O, Roman Y. The frequency of major ABCG2, SLCO1B1 and CYP2C9 variants in Asian, Native Hawaiian and Pacific Islander women subgroups: implications for personalized statins dosing. Pharmacogenomics 2023;24(7):381–98.
7. Lee YJ, Hong SJ, Kang WC, et al. Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial. BMJ 2023;383:e075837.
8. Shin JI, Fine DM, Sang Y, et al. Association of rosuvastatin use with risk of hematuria and proteinuria. J Am Soc Nephrol 2022;33(9):1767–77.